Suppr超能文献

优化良性前列腺增生症的管理。

Optimizing the management of benign prostatic hyperplasia.

出版信息

Ther Adv Urol. 2012 Apr;4(2):77-83. doi: 10.1177/1756287212437361.

Abstract

One of the challenges facing primary care physicians and specialists as the population ages is the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). While as many as 18% of men in their 40s report bother from an enlarged prostate, that figure rises dramatically, whereby 50% of men in their 50s and 90% of men in their 90s will complain of bothersome symptoms related to an enlarged prostate. Studies have shown that BPH is a progressive disease, which if left untreated can result in worsening of symptoms, acute urinary retention and renal failure. Until about 20 years ago the only management option available to urologists was surgery. In the early 1990s medical therapy emerged as the predominant treatment for BPH. Therapy may be tailored to target symptoms and progression of disease.

摘要

随着人口老龄化,初级保健医生和专家面临的挑战之一是管理良性前列腺增生(BPH)引起的下尿路症状(LUTS)。虽然多达 18%的 40 多岁男性报告因前列腺增大而感到不适,但这一数字急剧上升,50%的 50 多岁男性和 90%的 90 多岁男性会抱怨与前列腺增大相关的恼人症状。研究表明,BPH 是一种进行性疾病,如果不治疗,可能会导致症状恶化、急性尿潴留和肾衰竭。直到大约 20 年前,泌尿科医生唯一可用的治疗选择是手术。20 世纪 90 年代初,药物治疗成为 BPH 的主要治疗方法。治疗方法可以根据症状和疾病进展进行调整。

相似文献

1
Optimizing the management of benign prostatic hyperplasia.
Ther Adv Urol. 2012 Apr;4(2):77-83. doi: 10.1177/1756287212437361.
3
Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
BJU Int. 2009 Oct;104(7):974-83. doi: 10.1111/j.1464-410X.2009.08503.x. Epub 2009 May 7.
4
Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. doi: 10.1016/s1543-5946(05)00031-0.
7
BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
BJU Int. 2008 Mar;101 Suppl 3:17-21. doi: 10.1111/j.1464-410X.2008.07497.x.
8
Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
World J Urol. 2020 Nov;38(11):2771-2779. doi: 10.1007/s00345-020-03106-1. Epub 2020 Feb 14.
9
Risk stratification for benign prostatic hyperplasia.
Urologia. 2017 Aug 1;84(3):153-157. doi: 10.5301/uro.5000220. Epub 2017 Mar 18.
10
Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.
World J Urol. 2010 Feb;28(1):9-15. doi: 10.1007/s00345-009-0493-y. Epub 2009 Dec 3.

本文引用的文献

4
Update on AUA guideline on the management of benign prostatic hyperplasia.
J Urol. 2011 May;185(5):1793-803. doi: 10.1016/j.juro.2011.01.074. Epub 2011 Mar 21.
6
Antimuscarinic mechanisms and the overactive detrusor: an update.
Eur Urol. 2011 Mar;59(3):377-86. doi: 10.1016/j.eururo.2010.11.040. Epub 2010 Dec 8.
7
Etiology, epidemiology, and natural history of benign prostatic hyperplasia.
Urol Clin North Am. 2009 Nov;36(4):403-15, v. doi: 10.1016/j.ucl.2009.07.003.
9
Evaluation and treatment of lower urinary tract symptoms in older men.
J Urol. 2009 Apr;181(4):1779-87. doi: 10.1016/j.juro.2008.11.127. Epub 2009 Feb 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验